These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacologic and radioligand binding studies of 1,4-dihydropyridines in rat cardiac and vascular preparations: stereoselectivity and voltage dependence of antagonist and activator interactions.
    Author: Zheng W, Stoltefuss J, Goldmann S, Triggle DJ.
    Journal: Mol Pharmacol; 1992 Mar; 41(3):535-41. PubMed ID: 1372088.
    Abstract:
    The pharmacologic and radioligand-binding properties of 1,4-dihydropyridines in an activator (Bay K 8644) and an antagonist (nifedipine) series were studied in rat tail artery, heart membrane, and neonatal rat ventricular myocytes. The S-enantiomers of the activator series contracted rat tail artery in the presence of 15 mM K+ (EC50 values of 10(-8) to 10(-5) M). (S)-Bay K 8644 (I) and its o-difluoromethoxy analog (III) were the most potent members of the activator series examined. The abilities of the activators to stimulate maximum tension response of the artery differed with structure; thus, the efficacy of (S)-Bay K 8644 was 70% that of the analog lacking the 3-carbomethoxy group. The R-enantiomers of the activator series and a series of achiral nifedipine analogs were inhibitory in the same tissue. The intact-cell binding assay revealed the binding affinities of 1,4-dihydropyridine antagonists in depolarized cells (50 mM K+) to be higher than those in polarized cells (5 mM K+). The ratio KD (polarized)/KD (depolarized) was 77 for nifedipine (IC50 = 5.4 x 10(-9) M) but was only 2.9 for the weak 3-methoxy nifedipine analog (IC50 = 4.8 x 10(-6) M); an approximately linear relationship exists between this ratio and the antagonist potency. In marked contrast, and in confirmation of previous work [Mol. Pharmacol. 35:541-552 (1989)], the binding affinities of activators were not significantly affected by membrane potential, regardless of potency. We conclude that the S-enantiomers of Bay K 8644 analogs are activators with different potency and efficacy and that the R-enantiomers are antagonists, that the binding of 1,4-dihydropyridine antagonists is voltage dependent, whereas binding of the activators is not, and that the voltage-dependence of binding of the antagonists is correlated with the potency of the antagonist.
    [Abstract] [Full Text] [Related] [New Search]